• Users Online: 28
  • Print this page
  • Email this page
Year : 2022  |  Volume : 10  |  Issue : 3  |  Page : 121-123

Cariprazine: A complete solution for full-spectrum bipolar I disorder?

Department of Psychiatry, Murshidabad Medical College & Hospital, Kolkata, West Bengal, India

Correspondence Address:
Ranjan Bhattacharyya
Department of Psychiatry, Murshidabad Medical College & Hospital, 29, Anandasree, Garia, Kolkata 700084, West Bengal
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/DYPJ.DYPJ_61_21

Rights and Permissions

Cariprazine is a partial agonist of dopamine and serotonin with high affinity for D3 receptor. There is excess endogenous dopamine both in schizophrenia and bipolar disorder. Cariprazine binds to D3/D2 receptor as antagonist and agonist in schizophrenia and bipolar depression, respectively. Thus, the dopamine pathway inhibited and stimulated in the respective cases. The United States Food and Drug Administration (USFDA) approval now covers the full-spectrum Bipolar I disorder, yet to hit the Indian market.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded21    
    Comments [Add]    

Recommend this journal